![Jun Gong: Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors](https://oncodaily.com/pub/uploads/2024/06/Jun-Gong-ff-1280x705.jpeg)
Photo taken from Jun Gong/X
Jun 7, 2024, 06:44
Jun Gong: Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors
Jun Gong, Medical oncologist and researcher in gastrointestinal and genitourinary cancers at Cedars-Sinai, shared a post on X:
“Dr. Fang PhI trial hypoxia-responsive CEA CAR-T in refractory solid tumors (35/40 #mCRC pts) enrolled to IV or IP administration depending on predominant peritoneal Mets. IP ORR 25% vs 8% IV, 100% G3-4 heme toxicity, G1-2 CRS 62.5% all patients.”
Source: Jun Gong/X
Jul 4, 2024, 00:09